(Q33395088)

26 July 2017

Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial (English)

1 reference

26 July 2017

phase I clinical trial

0 references

1 reference

Lionel S Zuckier

4

0 references

author name string

Seza A Gulec

1

1 reference

26 July 2017

Steven J Cohen

2

1 reference

26 July 2017

Kenneth L Pennington

3

1 reference

26 July 2017

Ralph J Hauke

5

1 reference

26 July 2017

Heather Horne

6

1 reference

26 July 2017

William A Wegener

7

1 reference

26 July 2017

Nick Teoh

8

1 reference

26 July 2017

David V Gold

9

1 reference

26 July 2017

Robert M Sharkey

10

1 reference

26 July 2017

David M Goldenberg

11

1 reference

26 July 2017

language of work or name

English

0 references

publication date

28 April 2011

1 reference

26 July 2017

Clinical Cancer Research

1 reference

26 July 2017

17

1 reference

26 July 2017

12

1 reference

26 July 2017

4091-4100

1 reference

Detection of early-stage pancreatic adenocarcinoma

26 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048986

High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048986

Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048986

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048986

Perspectives on cancer therapy with radiolabeled monoclonal antibodies.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048986

Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048986

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048986

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048986

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048986

Bone marrow dosimetry for radioimmunotherapy: theoretical considerations.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048986

PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048986

Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048986

90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048986

Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048986

Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048986

Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin

10 December 2018

1 reference

12 December 2020

Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4

1 reference

12 December 2020

MIRDOSE: personal computer software for internal dose assessment in nuclear medicine

1 reference

12 December 2020

Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4

1 reference

12 December 2020

New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis

1 reference

12 December 2020

Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer

1 reference

12 December 2020

10.1158/1078-0432.CCR-10-2579

Identifiers

DOI

1 reference

26 July 2017

1 reference

26 July 2017

1 reference